Please login to the form below

Not currently logged in

Celgene's cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus
Istodax romidepsin - Celgene

A cancer drug sold by Celgene could be used to drive HIV from hidden reservoirs within the body so the virus becomes susceptible to antiretroviral therapy, according to a new study.

The results of a small study in six HIV-positive patients - reported at the Aids 2014 congress in Melbourne this week - are important because tackling HIV reservoirs is considered critical if therapy is ever to result in a cure rather than long-term viral suppression.

Study leader Ole Schmeltz Søgaard from Aarhus University in Denmark said that administering a low dose of peripheral T cell lymphoma (PTCL) therapy Istodax (romidepsin) to patients on antiretroviral therapy - who had no detectable virus particles in the blood - boosted HIV transcription in cells by two to four times.

Viral load in the blood rose in five of six patients who were given three infusions of the drug over a two-week period, although levels fell back quickly after the drug was discontinued and there is no way of knowing at the moment how much of the latent virus was flushed into the open.

The news last week of the re-emergence of HIV in the 'Mississippi baby' - an infant girl thought to have been cured of HIV through the early use of potent anti-HIV drugs - has revealed how important it is to prevent the virus hiding away in the body, particularly in light of new data suggesting that these reservoirs form even before the virus is detectable in the blood.

One disappointing aspect of the study, called REDUC, was that there was no evidence that the body mounted a renewed immune response after the latent virus particles were released.

Søgaard and his colleagues now intend to expand their studies to see how this HIV-mobilising therapy can be deployed alongside immune-stimulating approaches that can prime the body to respond to the newly-released HIV particles.

The study was part of a project sponsored by Bionor Pharma, a Norwegian biopharma company that is developing romidepsin alongside its therapeutic vaccine candidate Vacc-4x in a two-part treatment regimen for HIV.

The second stage in the REDUC trial that will test the activity of romidepsin followed by Vacc-4x has started enrolling patients and is scheduled to generate results next year. 

Vacc-4x is made from modified, synthetic peptides, targeting conserved regions on HIV's p24 antigen.

23rd July 2014

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....